Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer
Authors:
Open Access
- 8 June 2010
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (1) , 101-111
Abstract
Background: In renal cell carcinoma (RCC), the discovery of biomarkers for clinical use is a priority. This study aimed to identify and validate diagnostic and prognostic serum markers using proteomic profiling. Methods: Pre-operative sera from 119 patients with clear cell RCC and 69 healthy controls was analysed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry with stringent in-house quality control and analysis routines. Following identification of one prognostic peak as a fragment of serum amyloid A (SAA), total serum SAA and CRP were also determined by immunoassay for further validation. Results: Several peptides were identified as having independent prognostic but not diagnostic significance on multivariable analysis. One was subsequently identified as a 1525 Da fragment of SAA (hazard ratio (HR)=0.26, 95% CI 0.08–0.85, P=0.026). This was weakly negatively correlated with total SAA, which was also of independent prognostic significance (HR=2.46, 95% CI 1.17–5.15, P=0.017). Both potentially strengthened prognostic models based solely on pre-operative variables. Conclusions: This is the first description of the prognostic value of this peptide in RCC and demonstrates proof of principle of the approach. The subsequent examination of SAA protein considerably extends previous studies, being the first study to focus solely on pre-operative samples and describing potential clinical utility in pre-operative prognostic models.Keywords
This publication has 47 references indexed in Scilit:
- Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaClinical Cancer Research, 2009
- Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical ApplicabilityEuropean Urology, 2009
- Integrated multi-level quality control for proteomic profiling studies using mass spectrometryBMC Bioinformatics, 2008
- Proteomic Contributions to Personalized Cancer CareMolecular & Cellular Proteomics, 2008
- Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populationsLaboratory Investigation, 2007
- Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitationsClinical Chemistry and Laboratory Medicine (CCLM), 2007
- Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor AggressivenessClinical Cancer Research, 2005
- Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patientsLaboratory Investigation, 2004
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeClinical Chemistry, 2003
- The acute phase protein response in patients receiving subcutaneous IL-6Clinical and Experimental Immunology, 1995